In the setting of intensive immunosuppression for the management of rejection in solid organ
transplant (SOT) recipients, or graft-versus-host disease (GVHD) in hematopoietic stem cell …

In the past 4 years, interest in drug-resistant herpesviruses has evolved from the realm of
academic laboratory studies to that of great clinical importance. Recurrent and persistent …

Antiviral agents are commonly used for cytomegalovirus (CMV) prophylaxis or therapy after
solid organ transplantation. Until recently, the detection of drug‐resistant CMV in this setting …

We examined the rate, clinical impact, and risk factors of cytomegalovirus (CMV) drug
resistance in 561 patients who underwent 616 hematopoietic stem cell transplantations …

Herpes simplex virus (HSV) infections in 75 allogeneic stem cell transplant recipients were
analyzed. Sixteen patients developed HSV disease following transplantation. The risk …

The discovery of acyclovir (ACV), a nucleoside analogue, more than 30 years ago,
represents a milestone in the management of HSV and VZV infections. The modest activity …

Human cytomegalovirus (HCMV) infection is a major cause of morbidity and mortality in
allogeneic hematopoietic stem cell transplant recipients. The significant clinical impact of …

The emergence of human cytomegalovirus (HCMV) drug resistant strains is a life-
threatening condition in immunocompromised individuals with active HCMV infection …

Despite advances in preventive strategies, cytomegalovirus (CMV) infection remains a major
complication in solid organ and hematopoietic cell transplant recipients. CMV infection may …

Cytomegalovirus (CMV) infection is a significant complication in hematopoietic cell
transplantation (HCT) recipients. Four antiviral drugs are used for preventing or treating …